• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer

    7/7/21 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OTLK alert in real time by email
    • Experienced executive with a track-record of successful eye care product launches
    • Appointment reflects Outlook Therapeutics' dedication to transition to commercial-stage company

    ISELIN, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the appointment of C. Russell Trenary III as President, Chief Executive Officer and a member of the Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics' President, CEO and CFO since June 2018, will continue serving as CFO and as a member of the Board of Directors.

    "We are pleased to welcome Russ to the executive leadership team. We believe his leadership and expertise is an invaluable asset as we look to optimize our position in the retina industry and prepare to submit a Biologics License Application (BLA) for ONS-5010 and, if approved, launch our commercialization efforts. With the addition of Russ, we have the right leadership team to develop a fully integrated ophthalmic company," stated Randy Thurman, Executive Chairman of the Outlook Therapeutics Board of Directors.

    Mr. Trenary brings over 35 years of experience in the life sciences industry, specifically in medical ophthalmic implant sales, marketing, and business development. Over the course of his career, he has closely led four major product launches in eye care medical devices. Additionally, Mr. Trenary has played a key role in seven acquisitions including, most recently, the sale of InnFocus, Inc. to Santen.

    "I am thrilled to be joining Outlook Therapeutics at such a critical point in the company's history. If approved, ONS-5010 represents a rare opportunity to transform the standard of care and significantly impact the retina market for years to come," commented Mr. Trenary, President and Chief Executive Officer of Outlook Therapeutics. "I would like to congratulate Larry and the rest of the executive leadership team for their efforts in bringing Outlook Therapeutics to this transition point. I look forward to building on this momentum and driving Outlook Therapeutics to the next transformational phase of growth."

    Mr. Trenary joins Outlook Therapeutics having most recently served as an Executive Advisor at InnFocus Inc., after serving as President & CEO for seven years, including the company's acquisition in August 2016 by Santen Pharmaceutical Co., Ltd. InnFocus is an early-stage company, pending FDA approval of the PRESERFLO MicroShunt® glaucoma device, and other microsurgical solutions for glaucoma based on SIBS technology. Prior to that, he served as President and CEO of G&H Orthodontics, a global medical device company, and served in a number of senior leadership positions at Advanced Medical Optics (AMO), Inc., including as President of the cataract business unit. Prior to that, Mr. Trenary held C-suite positions at Sunrise Technologies International, Inc., served as Senior Vice President, Worldwide Sales & Marketing / Officer at VidaMed, Inc. and held several senior leadership roles at Allergan, Inc., including as Senior Vice President and General Manager of the Medical Optics business unit.

    Mr. Thurman on behalf of the Board of Outlook Therapeutics added, "We are very fortunate to be able to bring Russ on to the Outlook Therapeutics team at this important point in the ONS-5010 program. Russ' history of providing experienced CEO leadership, multiple successful eye health related product launches and value creation for shareholders will be important as we turn our focus to building Outlook Therapeutics and launching the next phase for ONS-5010. We are excited about the continued evolution of Outlook Therapeutics and believe we are poised for continued progress in the near and long-term. Furthermore, the Board would like to thank Larry Kenyon who has served as Outlook's President, CEO and CFO for the last 3 years. During that time, Larry successfully restructured the company, completed several rounds of fundraising and led Outlook Therapeutics to this successful moment of transition. We are very pleased that Larry will continue as Chief Financial Officer and a member of our Board."

    Outlook Therapeutics remains on track to report topline data from its pivotal NORSE TWO safety and efficacy study evaluating ONS-5010 (bevacizumab-vikg) for treatment of wet age-related macular degeneration (wet AMD) in the third calendar quarter of 2021. Following the data readout for NORSE TWO, Outlook Therapeutics plans to submit a new BLA filing under the PHSA 351(a) regulatory pathway in the first quarter of calendar 2022. If the BLA is approved, it will result in 12 years of marketing exclusivity for ONS-5010 as the first and only ophthalmic formulation of bevacizumab approved by the FDA to treat wet AMD.

    Outlook Therapeutics is also developing registration documents on a parallel path for approvals in Europe and expects to submit them shortly after completing the filing to the FDA. While Outlook Therapeutics continues to target potential strategic commercialization partners, particularly for European markets, it is preparing to launch ONS-5010 in the United States by itself, pending FDA approval.

    About Outlook Therapeutics, Inc.

    Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 ophthalmic bevacizumab with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

    Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts are "forward-looking statements," including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "project," "believe," "estimate," "predict," "potential," "intend" or "continue," the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, statements about the timing of completion of, and pivotal safety and efficacy data from, NORSE 2, ONS-5010's potential as the first FDA-approved ophthalmic formulation of bevacizumab-vikg, including benefits therefrom to patients, payors and physicians, including expectations of market exclusivity, the timing of BLA submission and commercial launch of ONS-5010, and plans for regulatory approvals in other markets. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, as well as those risks detailed in Outlook Therapeutics' filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the fiscal year ended September 30, 2020, as amended, and subsequent Quarterly Reports on Form 10-Q, which include the uncertainty of future impacts related to the ongoing COVID-19 pandemic. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

    CONTACTS:

    Media Inquiries:

    Harriet Ullman

    Vice President

    LaVoie Health Science

    T: 617-669-3082

    [email protected]

    Investor Inquiries:

    Jenene Thomas

    Chief Executive Officer

    JTC Team, LLC

    T: 833.475.8247 

    [email protected]



    Primary Logo

    Get the next $OTLK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OTLK

    DatePrice TargetRatingAnalyst
    8/29/2025Buy → Neutral
    H.C. Wainwright
    8/28/2025Buy → Neutral
    Guggenheim
    12/2/2024Buy → Neutral
    Chardan Capital Markets
    3/27/2024$50.00Neutral → Buy
    BTIG Research
    2/15/2024$3.00Neutral → Buy
    Chardan Capital Markets
    1/25/2024Neutral → Buy
    Guggenheim
    12/27/2023$5.00Equal Weight → Overweight
    CapitalOne
    8/31/2023$5.00 → $1.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $OTLK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

    ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris. Details for the presentations are as follows: Session: VEGF Related and Other Retinal Indications Title: Optimising the treatment of retinal diseasePresenter: Bob Jahr, Chief Executive Officer of Outlook TherapeuticsDate and Time: Wednesday, September 3, 2025, 16:10 PM CEST / 10:10 AM EDT For more inf

    9/3/25 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Requests Type A Meeting with FDA

    ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. In the FDA's recently issued CRL, although the Agency acknowledged the NORSE TWO pivotal trial met its safety and efficacy endpoint

    9/2/25 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

    FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAOutlook Therapeutics plans to work with FDA to address the Agency's issuesCompany to host a conference call and webcast today, August 28th at 8:30 AM ET ISELIN, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to its biologics license application (BLA) resubmission, indicating that the FDA cannot approve the application in its present form for the treat

    8/28/25 6:30:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OTLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Jahr Robert Charles

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    7/9/25 5:17:49 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Jahr Robert Charles

    3 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    7/9/25 5:16:55 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sukhtian Ghiath M. was granted 4,285,714 shares (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    5/28/25 5:20:21 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OTLK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kenyon Lawrence A bought $28,446 worth of shares (5,000 units at $5.69), increasing direct ownership by 529% to 5,946 units (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    9/30/24 4:53:23 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Syntone Ventures Llc bought 714,286 shares, increasing direct ownership by 72% to 1,705,438 units (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    4/17/24 8:21:17 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Haddadin Yezan Munther bought $22,242 worth of shares (1,882 units at $11.82), increasing direct ownership by 59% to 5,049 units (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    3/29/24 10:39:09 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OTLK
    SEC Filings

    View All

    Outlook Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    9/5/25 5:00:49 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    9/2/25 5:00:49 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Outlook Therapeutics Inc.

    SCHEDULE 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    8/14/25 5:15:38 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OTLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Outlook Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Outlook Therapeutics from Buy to Neutral

    8/29/25 8:20:01 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Outlook Therapeutics from Buy to Neutral

    8/28/25 12:48:22 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded Outlook Therapeutics from Buy to Neutral

    12/2/24 10:06:30 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OTLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

    SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    11/14/24 4:55:26 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

    SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    11/7/24 4:17:05 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Outlook Therapeutics Inc. (Amendment)

    SC 13D/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    4/17/24 9:38:26 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OTLK
    Leadership Updates

    Live Leadership Updates

    View All

    Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

    Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver results ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointment of Bob Jahr as Chief Executive Officer (CEO). Mr. Jahr has also been appointed to the Outlook Therapeutics Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics' Chie

    7/1/25 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

    ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced Faisal G. Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Mr. Sukhtian will assume the role from Randy Thurman, who will remain on the Board as Lead Independent Director. "On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest

    1/31/25 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics® Announces Executive Leadership Transition

    ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company's President and Chief Executive Officer (CEO), effective immediately. Lawrence Kenyon, Executive Vice President, Chief Financial Officer and member of the board of directors, has been appointed Interim CEO. "On behalf of our management team

    12/3/24 4:30:00 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OTLK
    Financials

    Live finance-specific insights

    View All

    Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

    FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAOutlook Therapeutics plans to work with FDA to address the Agency's issuesCompany to host a conference call and webcast today, August 28th at 8:30 AM ET ISELIN, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to its biologics license application (BLA) resubmission, indicating that the FDA cannot approve the application in its present form for the treat

    8/28/25 6:30:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

    First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in EuropeONS-5010/LYTENAVA™ (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United States ISELIN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the third quarter of fiscal year 2025 and provided a corporate update. Financial Highlights for the Fiscal Third Quarter Ended June 30, 2025For the fiscal third quarter ended June 30, 2025, Outlook Therapeutics reported net

    8/14/25 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

    LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the second quarter of fiscal year 2025 and provided a corporate update. "Outlook Therapeutics remains on track in 2025 to transform into a commercial-stage company with the planned upcoming commercial launch of LYTENAVA™ (bevaciz

    5/15/25 4:01:00 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care